Currently, several targets, such as Her-2 (NCT04650451), ROR1 (NCT02706392), and mesothelin (NCT02580747), are being studied in clinical trials of CAR-T cell therapy for breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.